Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials
about
Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysisHypothyroidism and its rapid correction alter cardiac remodelingCall for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical useB-type natriuretic peptide-guided treatment for heart failure.The potential value of integrated natriuretic peptide and echo-guided heart failure management.Protocol for a systematic review and individual participant data meta-analysis of B-type natriuretic peptide-guided therapy for heart failure.Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patientsRationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.Charting a roadmap for heart failure biomarker studies.Aerobic exercise effect on prognostic markers for systolic heart failure patients: a systematic review and meta-analysis.Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials.The human cardiac and skeletal muscle proteomes defined by transcriptomics and antibody-based profiling.1,25-Dihydroxyvitamin D to PTH(1-84) Ratios Strongly Predict Cardiovascular Death in Heart Failure.Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.A review on B-type natriuretic peptide monitoring: assays and biosensorsNeuro-hormonal effects of physical activity in the elderly.Effects of exercise on cardiovascular performance in the elderly.Heart failure in patients presenting with dyspnoea to the emergency department in the Asia Pacific region: an observational study.Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin.Old and new tools to assess dyspnea in the hospitalized patient.Natriuretic peptide-guided heart failure management.Natriuretic peptides in cardiovascular diseases: current use and perspectivesEffects of exercise training on cardiovascular adrenergic system.B-type natriuretic peptide-guided therapy: a systematic review.NT-proBNP and Echocardiographic Parameters for Prediction of Cardiovascular Outcomes in Patients with CKD Stages G2-G4.Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure.Prognostic value of galectin-3 in patients with heart failure.Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014).The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management.Galectin-3 correlates with arrhythmogenic right ventricular cardiomyopathy and predicts the risk of ventricular -arrhythmias in patients with implantable defibrillators.Can Natriuretic Peptides be Used to Guide Therapy?ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure.Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment.The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent Heart Failure and Death in Patients with Stable Coronary Artery Disease: The Heart and Soul Study.Brain natriuretic peptide-guided management of chronic heart failure: first do no harm.Pharmacogenomics of the Natriuretic Peptide System in Heart Failure.Heart failure readmissions.Saliva and plasma levels of cardiac-related biomarkers in post-myocardial infarction patients.
P2860
Q27012693-23B466FB-62C8-4BB9-B108-E25803551ABEQ27339180-A4CFFAE8-0F4A-42B7-ABF1-3C0975BDB5CAQ28081433-292F5301-8B7A-4A4E-8455-7D21AB14FBDBQ30238936-227D412F-97B0-4114-B87D-3DA8DF6A5DD0Q30434020-97B47DF5-8A71-4876-8E53-EDCC625274A1Q33960469-19387BA3-B3D4-4793-978F-A178AD8115C1Q34250674-2962658C-8839-45BF-BFF2-12585F8206DFQ34324771-C1F10971-522C-4A74-8F20-121A244DAAF8Q34324812-5A1760DB-DF5A-467E-9848-0CC6908F96A8Q35017888-75835D67-B368-4948-93FD-F16AD5F3CA66Q35179984-825F1BBA-88B2-4D2E-922F-0995BA585E45Q35673626-533D8D99-3AEF-498F-8DF0-F39B023F1D9AQ35755817-536D2D1A-FF99-41C4-A26C-E572CF04736BQ35792547-F72BC5D5-9404-44CA-88EF-A105038BB70FQ37171880-DC9089FC-C9EB-417A-AA01-FB02D13B0EE4Q37404953-9087773B-0F71-4706-B936-AFC8820FFFDAQ37594289-6B062F80-BFE7-4E84-967B-D43CFC9E8BFDQ37681401-0F13BDE1-A20E-4410-9153-F7C105E8DAA0Q38096829-C693E12F-0462-4242-ABCD-729D2655DB4CQ38114009-0F97DBFA-9D1F-4CA3-840E-8224CBE1CAE3Q38161695-F7A06022-2D2F-4551-B2C3-CDC778CC052AQ38162429-584C7A80-7372-4828-9725-B0A37EFEB147Q38172127-01E226CB-F526-42DA-85BC-C7C9C113E4E3Q38235223-3CA353B7-F44E-4939-9C45-09DE1CE9C3A8Q38378152-280C95BF-C35F-489E-B9DB-DB36D039E6AFQ38424871-CADCD460-C838-4C28-9500-276AC5BAED85Q38471023-A4601B3E-1A1A-43E6-9C60-9C811B8B845AQ38546917-99DDDF8D-BD1E-4F7D-9C44-C08131742DD5Q38551693-1F28046F-5523-4884-A64D-A5982B81D38FQ38680570-A9B3C485-4F09-4413-9C98-92D34D4D4179Q38967512-D088A234-23A2-4F7D-83F1-7FE4446C7CA1Q41083010-96730CB4-F885-44B2-8CD9-FD9FBC5061C0Q41239335-AF8489D2-2A24-4A4D-B88B-6699484D957AQ41534613-4AFBA1CB-8B71-459E-95B8-668D2B940CDEQ42646632-DE2E5D90-5F21-4131-BCD3-7A4581C2002DQ44540336-6097C7E0-FEA5-45CF-8BF5-C00770E69EFCQ44566168-F5D720C1-7B64-4244-98BF-334ACAD1D401Q47596916-81A865B6-C9CD-4B33-948C-20A96B378157Q48003695-86BA07E9-5BA5-48D9-8322-0C06AA2FAA33Q48217947-D8C6A64C-48EC-46C6-BF56-2769470E82E5
P2860
Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Natriuretic peptide-guided the ...... tients in 12 randomized trials
@ast
Natriuretic peptide-guided the ...... tients in 12 randomized trials
@en
Natriuretic peptide-guided the ...... tients in 12 randomized trials
@nl
type
label
Natriuretic peptide-guided the ...... tients in 12 randomized trials
@ast
Natriuretic peptide-guided the ...... tients in 12 randomized trials
@en
Natriuretic peptide-guided the ...... tients in 12 randomized trials
@nl
prefLabel
Natriuretic peptide-guided the ...... tients in 12 randomized trials
@ast
Natriuretic peptide-guided the ...... tients in 12 randomized trials
@en
Natriuretic peptide-guided the ...... tients in 12 randomized trials
@nl
P2093
P2860
P50
P1433
P1476
Natriuretic peptide-guided the ...... tients in 12 randomized trials
@en
P2093
Francesco Gambardella
Maria Prastaro
Pasquale Perrone-Filardi
Santo Dellegrottaglie
P2860
P304
P356
10.1371/JOURNAL.PONE.0058287
P407
P577
2013-03-05T00:00:00Z